Latest News
Partnership to focus on Alzheimer’s disease, breast cancer, diabetes, obesity
Reading Time: 8 minutes
Centene Corporation (NYSE: CNC) and Washington University School of Medicine in St. Louis announced today a partnership to transform and accelerate research into treatments for Alzheimer’s disease, breast cancer, diabetes and obesity. All are common, debilitating and often deadly diseases that affect millions of people worldwide, at all levels of income.
As part of the partnership, Centene will fund up to $100 million over 10 years in research at Washington University. The funding will galvanize the School of Medicine’s Personalized Medicine Initiative, which aims to develop customized disease treatment and prevention for patients. Innovations that arise from the initiative will be commercialized through the ARCH Personalized Medicine Initiative, a joint venture between the School of Medicine and Centene. Reflecting the philosophy of both institutions, ARCH is designed to accelerate the development and implementation of affordable and accessible health solutions to the public using the intellectual property developed from this research.
“We share the goal of helping to improve the health of our communities through research, education and customized treatment for people suffering from chronic illnesses,” said Michael F. Neidorff, chairman and CEO for Centene. “We believe personalized medicine is the path to ensure patients get the targeted health care they need to fight disease, and we look forward to partnering with such a renowned medical school to initially focus on four diseases that impact millions of Americans, including many of our health plan members.”
The investment will leverage the university’s cutting-edge research and biomedical capabilities, including state-of-the-art technologies such as CRISPR, and internationally known scientists in the areas of the microbiome, immunomodulatory therapies, cancer genomics, neurodegeneration, cellular reprogramming, chemical biology, informatics and others. In addition, the funds will strengthen resources at more than a dozen centers and institutes at the School of Medicine, including the Edison Family Center for Genome Sciences & Systems Biology; the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; the Elizabeth H. and James S. McDonnell III Genome Institute; the Institute for Informatics; and the Center of Regenerative Medicine.
“We will be bringing together world-class resources and intellectual horsepower from every basic and clinical scientific discipline to urgently accelerate the timeline for developing therapies that are more precisely targeted, with aspirations to do so in the next five to seven years,” said David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean, and the Spencer T. and Ann. W. Olin Distinguished Professor at the School of Medicine. “I believe the most important advances that will evolve from the personalized medicine paradigm will come from harnessing genome engineering technologies to build better model systems of each human disease, and utilizing deep genomic and clinical characterization to enable more effective and less expensive clinical trials.”
Perlmutter continued, “The partnership supports our global leadership in understanding sequence variants in biological systems that will pave the way for new therapeutic targets, as well as learning more about our own innate biology. Once personalized medicine becomes common practice, health-care workers may examine each patient’s genome — as well as information regarding his or her environment, lifestyle and social network — to identify a customized, affordable approach to optimizing health and medical care.”
Centene and Washington University will host a press briefing at a later date to be determined.
About Centene Corporation
Centene Corporation, a Fortune 100 company, is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children’s Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and Long-Term Services and Supports (LTSS), in addition to other state-sponsored programs, Medicare (including the Medicare prescription drug benefit commonly known as “Part D”), dual eligible programs and programs with the U.S. Department of Defense. Centene also provides healthcare services to groups and individuals delivered through commercial health plans. Centene operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health management, care management software, correctional healthcare services, dental benefits management, commercial programs, home-based primary care services, life and health management, vision benefits management, pharmacy benefits management, specialty pharmacy and telehealth services.
Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene’s investor relations website, http://www.centene.com/investors.
About Washington University School of Medicine in St. Louis
Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.
Cautionary Statement on Forward-Looking Statements
All statements, other than statements of current or historical fact, contained in this communication are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “seek,” “target,” “goal,” “may,” “will,” “would,” “could,” “should,” “can,” “continue” and other similar words or expressions (and the negative thereof). We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and Centene Corporation is including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about Centene’s future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of Centene’s proposed acquisition of WellCare Health Plans, Inc. (the “WellCare Transaction”), Centene’s recent acquisition (the “Fidelis Care Transaction”) of substantially all the assets of New York State Catholic Health Plan, Inc., d/b/a Fidelis Care New York (“Fidelis Care“), investments and the adequacy of Centene’s available cash resources.
These forward-looking statements reflect Centene’s current views with respect to future events and are based on numerous assumptions and assessments made by us in light of Centene’s experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors Centene believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause Centene’s or its industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions.
All forward-looking statements included in this filing are based on information available to us on the date of this communication. Except as may be otherwise required by law, Centene undertakes no obligation to update or revise the forward-looking statements included in this communication, whether as a result of new information, future events or otherwise, after the date of this filing. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to, the following: (i) the risk that regulatory or other approvals required for the WellCare Transaction may be delayed or not obtained or are obtained subject to conditions that are not anticipated that could require the exertion of management’s time and Centene’s resources or otherwise have an adverse effect on Centene; (ii) the risk that Centene’s stockholders do not approve the issuance of shares of Centene common stock in the WellCare Transaction; (iii) the risk that WellCare’s stockholders do not adopt the merger agreement; (iv) the possibility that certain conditions to the consummation of the WellCare Transaction will not be satisfied or completed on a timely basis and accordingly the WellCare Transaction may not be consummated on a timely basis or at all; (v) uncertainty as to the expected financial performance of the combined company following completion of the WellCare Transaction; (vi) the possibility that the expected synergies and value creation from the WellCare Transaction will not be realized, or will not be realized within the expected time period; (vii) the exertion of management’s time and Centene’s resources, and other expenses incurred and business changes required, in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for the WellCare Transaction; (viii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of the WellCare Transaction or that the integration of WellCare will be more difficult or time consuming than expected; (ix) the risk that potential litigation in connection with the WellCare Transaction may affect the timing or occurrence of the WellCare Transaction or result in significant costs of defense, indemnification and liability; (x) a downgrade of the credit rating of Centene’s indebtedness, which could give rise to an obligation to redeem existing indebtedness; (xi) unexpected costs, charges or expenses resulting from the WellCare Transaction; (xii) the possibility that competing offers will be made to acquire WellCare; (xiii) the inability to retain key personnel; (xiv) disruption from the announcement, pendency and/or completion of the WellCare Transaction, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; and (xv) the risk that, following the WellCare Transaction, the combined company may not be able to effectively manage its expanded operations.
Additional factors that may cause actual results to differ materially from projections, estimates, or other forward-looking statements include, but are not limited to, the following: (i) Centene’s ability to accurately predict and effectively manage health benefits and other operating expenses and reserves; (ii) competition; (iii) membership and revenue declines or unexpected trends; (iv) changes in healthcare practices, new technologies, and advances in medicine; (v) increased healthcare costs, (vi) changes in economic, political or market conditions; (vii) changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act, collectively referred to as the Affordable Care Act (“ACA”), and any regulations enacted thereunder that may result from changing political conditions or judicial actions, including the ultimate outcome of the District Court decision in “Texas v. United States of America” regarding the constitutionality of the ACA; (viii) rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting Centene’s government businesses; (ix) Centene’s ability to adequately price products on federally facilitated and state-based Health Insurance Marketplaces; (x) tax matters; (xi) disasters or major epidemics; (xii) the outcome of legal and regulatory proceedings; (xiii) changes in expected contract start dates; (xiv) provider, state, federal and other contract changes and timing of regulatory approval of contracts; (xv) the expiration, suspension, or termination of Centene’s contracts with federal or state governments (including but not limited to Medicaid, Medicare, TRICARE or other customers); (xvi) the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; (xvii) challenges to Centene’s contract awards; (xviii) cyber-attacks or other privacy or data security incidents; (xix) the possibility that the expected synergies and value creation from acquired businesses, including, without limitation, the Fidelis Care Transaction, will not be realized, or will not be realized within the expected time period; (xx) the exertion of management’s time and Centene’s resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions, including the Fidelis Care Transaction; (xxi) disruption caused by significant completed and pending acquisitions, including, among others, the Fidelis Care Transaction, making it more difficult to maintain business and operational relationships; (xxii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions, including, among others, the Fidelis Care Transaction; (xxiii) changes in expected closing dates, estimated purchase price and accretion for acquisitions; (xxiv) the risk that acquired businesses, including Fidelis Care, will not be integrated successfully; (xxv) the risk that, following the Fidelis Care Transaction, Centene may not be able to effectively manage its expanded operations; (xxvi) restrictions and limitations in connection with Centene’s indebtedness; (xxvii) Centene’s ability to maintain the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; (xxviii) availability of debt and equity financing, on terms that are favorable to us; (xxxix) inflation; and (xxx) foreign currency fluctuations.
This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect Centene’s business operations, financial condition and results of operations, in Centene’s filings with the Securities and Exchange Commission (the “SEC”), including Centene’s Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, Centene cannot give assurances with respect to Centene’s future performance, including without limitation Centene’s ability to maintain adequate premium levels or Centene’s ability to control its future medical and selling, general and administrative costs.
SOURCE: Centene Corporation
Latest News
Gen Z’s Engagement in the Sober Curious Movement Surges by 53% from 2023 to 2024, Reveals Latest NCSolutions Analysis
- Over one-third of Gen Zers (34%) say they’ll try a new beverage product if it’s marketed as aligning with the sober curious lifestyle.
- Nearly half (45%) of Gen Z say social media is the most effective advertising channel to inform them about new nonalcoholic options.
- The most popular month to purchase alcohol in 2023 was December (up 16% over November), and the least popular was January (down 24% compared to December 2022)
The share of Gen Zers born between 1997 and 2002 who say they plan to drink less alcohol in 2024 jumped 53% year over year. Sixty-one percent say they plan to cut back on their alcohol consumption, compared to 40% who said they planned to drink less in 2023.
The findings are from the latest consumer sentiment survey about the sober curious movement, a follow-up to a similar survey conducted in January 2023. Both surveys were commissioned by NCSolutions (NCS). The findings also include an analysis of NCS’ proprietary consumer purchase data. NCS is the leading company for improving advertising effectiveness for the consumer packaged goods (CPG) ecosystem.
More millennials (born between 1981 and 1996) said they’d drink less in 2024 (49%), an increase of 26% from those surveyed a year before. Overall, 41% of all Americans plan to drink less in 2024, up from 34% the year before. Together, these findings indicate the sober curious movement gained strength over the last year, largely due to interest from younger generations.
“Nonalcoholic alternatives, once a niche category, are becoming more mainstream,” said Alan Miles, chief executive officer, NCSolutions. “Younger consumers are increasingly expressing a growing interest in healthier options for social drinking. Beverage brands have a real opportunity to engage and build brand loyalty with the next generation of consumers by focusing on the right combination of creative, product, placement, and timing.”
Tap into Gen Z with sober curious lifestyle messages
Younger consumers say saving money and improving physical health are the top reasons they switch to a sober lifestyle. More than one-third (36%) of Gen Z say they’re going alcohol-free for their mental health.
This impacts the type of advertising most likely to influence purchases: over one-third of Gen Zers (34%) say they’re more likely to try a new beverage product if it’s aligned with the sober curious lifestyle, compared to 17% of all Americans. The finding adds further nuance to the marketing preferences of Gen Z, who are known to have an affinity for brands whose missions align with their values.
Nearly half (45%) of Gen Zers say social media is the most effective advertising channel to help them learn about new nonalcoholic beverage options, followed by internet searches (16%) and streaming TV (15%). In addition, nearly one in four (24%) have tried a nonalcoholic beverage because a celebrity or influencer endorsed it.
Mocktails are twice as popular as nonalcoholic beer
Sober curious consumers surveyed are twice as likely to choose a mocktail than a nonalcoholic beer. One in five (19%) Americans said they drank a mocktail in 2023, compared to one in 10 who drank nonalcoholic beer. More than one-third (37%) said they drank mocktails most often.
Mocktails were especially popular among younger generations in 2023. Thirty-seven percent of Gen Z said they drank mocktails last year, compared to 16% who said they had nonalcoholic beer and 10% who said they drank nonalcoholic wine.
Among millennials, 30% said they drank mocktails in 2023, compared to 15% who drank nonalcoholic beer and 9% who had nonalcoholic wine.
Seventeen percent of both millennials and Gen Z said they had tried THC and CBD-infused drinks in 2023.
December leads for nonalcoholic beverage sales
Interest in Dry and Damp January continues to expand. Consumers purchased the least amount of alcoholic beverages in January 2023 (down 24% from December 2022) and August 2023 (down 10% from July 2023), according to NCS purchase data. This follows a 19% drop in January 2022 compared to December 2021.
December was the most popular month of the year to buy alcohol in 2023, followed by May and March. Month-over-month purchases of alcohol in December increased 16% over November. This increase was two times higher than the 8% month-over-month increase in December 2022 and rose 8% in May, compared to April. By contrast, in 2022, the summer and winter holidays saw the highest increase in purchases of alcoholic beverages.
“Alcohol consumption is traditionally seasonal. Consumers purchase significantly more during December in preparation for the holidays,” Miles said. “In the past, we’ve seen alcohol sales rise during summer months, but now the peak is as early as May. Beverage brands have the opportunity to leverage the sober curious trend beyond January and into the summer months, targeting younger consumers with new summer-focused nonalcoholic products and health-oriented creative.”
Additional results are available on our website.
About NCS
NCSolutions (NCS) makes advertising work better. Our unrivaled data resources powered by leading providers combine with scientific rigor and leading-edge technology to empower the CPG ecosystem to create and deliver more effective advertising. With NCS’s proven approach, brands are achieving continuous optimization everywhere ads appear, through purchase-based audience targeting and sales measurement solutions that have impacted over $25 billion in media spend for our customers. Visit us at ncsolutions.com to learn more.
About the NCS Consumer Sentiment Survey
The consumer sentiment survey of 1,062 Americans was commissioned by NCS in December 2023 and was made up of U.S. adults ages 21+, who were asked about their drinking habits and preferences. Results were weighted to be representative of the U.S. population by age, gender, region, ethnicity, marital status, education level, and household income.
About NCS Purchase Data
NCS provides purchase insights to brands to help them target, optimize, measure, and enable sales-based outcomes. NCS’s representative and balanced consumer CPG purchase data set consists of the industry’s preeminent and comprehensive sources. It includes actual purchase data (transaction information) from big-box retailers, supermarkets, drug stores, convenience stores, and other retail channels at which American households buy CPG products spanning 340+ grocery categories. The NCSolutions purchase data was analyzed in January 2024.
Fair Use
When using this data and research, please attribute by linking to this study and citing NCSolutions.
SOURCE NCSolutions
Editor opinion:
The hemp, CBD, and related industries are likely to experience significant growth shortly, especially considering the increasing interest in soberness among Gen Z. The survey indicates that over one-third of Gen Zers (34%) are inclined to try new beverage products aligned with the sober curious lifestyle. This trend suggests a growing market for nonalcoholic alternatives, showcasing a shift towards healthier options for social drinking, including for sure hemp, and infused beverages.
Latest News
High Tide’s Raj Grover Clinches Spot on Grow Up’s 2024 Top 50 Cannabis Leaders in Canada List
High Tide Inc. (“High Tide” or the “Company“) (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, is pleased to announce that its Founder and CEO, Raj Grover, has made Grow Up’s 2024 Top 50 Cannabis Leaders in Canada list. The list, which was hand-selected by Grow Up’s industry advisory committee, recognizes influential leaders in the cannabis industry who are trailblazers in the growth, development, and innovation of the cannabis industry and celebrates their relentless, courageous, and innovative dedication to elevate the industry. The full list is available at Grow Up Top 50.
“I am honored to be included in this list. This would not have been possible without the continuous hard work and dedication of the High Tide team. Our innovative mindset has resulted in our ability to achieve significant milestones in the five years since Canadian legalization, despite broader industry challenges that have seen some of our peers fall by the wayside. Our success is also due to the loyalty and commitment of our customers, who continue to support our business in Canada and internationally,” said Raj Grover, Founder and Chief Executive Officer of High Tide.
“I also want to congratulate all the other industry trailblazers recognized on this list who are all leaders helping to shape and grow our industry. As we look to solidify our strength in Canada while exploring emerging markets in 2024, I know that our industry-leading team will continue delivering results for our customers and shareholders alike,” added Mr. Grover.
ABOUT RAJ GROVER
Raj Grover is one of Canada’s foremost business strategists and deal-makers who founded High Tide and its subsidiaries, Valiant Distribution, and Canna Cabana, and also co-founded Famous Brandz. Under his leadership, High Tide has grown from a small shop of 2 employees into Canada’s largest non-franchised cannabis retailer with over 160 locations and 1,500 team members globally. Raj has also expanded High Tide’s online reach in the ancillary cannabis space across North America and Europe. He is committed to giving back to the global community and has spearheaded High Tide’s support of World Vision, sponsoring over 300 children across 101 communities in 33 countries.
ABOUT HIGH TIDE
High Tide, Inc. is the leading community-grown, retail-forward cannabis enterprise engineered to unleash the full value of the world’s most powerful plant. High Tide (HITI) is uniquely built around the cannabis consumer, with wholly diversified and fully integrated operations across all components of cannabis, including:
Bricks & Mortar Retail: Canna Cabana™ is the largest non-franchised cannabis retail chain in Canada, with 162 current locations spanning British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario and growing. In 2021, Canna Cabana became the first cannabis discount club retailer in North America.
Retail Innovation: Fastendr™ is a unique and fully automated technology that integrates retail kiosks and smart lockers to facilitate a better buying experience through browsing, ordering, and pickup.
E-commerce Platforms: High Tide operates a suite of leading accessory sites across the world, including Grasscity.com, Smokecartel.com, Dailyhighclub.com, and Dankstop.com.
CBD: High Tide continues to cultivate the possibilities of consumer CBD through Nuleafnaturals.com, FABCBD.com, blessedcbd.de and blessedcbd.co.uk.
Wholesale Distribution: High Tide keeps that cannabis category stocked with wholesale solutions via Valiant™.
Licensing: High Tide continues to push cannabis culture forward through fresh partnerships and license agreements under the Famous Brandz™ name.
High Tide consistently moves ahead of the currents, having been named one of Canada’s Top Growing Companies in 2021, 2022 and 2023 by the Globe and Mail’s Report on Business Magazine and was ranked number one in the retail category on the Financial Times list of Americas’ Fastest Growing Companies for 2023. To discover the full impact of High Tide, visit www.hightideinc.com. For investment performance, don’t miss the High Tide profile pages on SEDAR+ and EDGAR.
ABOUT GROW UP
Since its inception in 2017, Grow Up Conference & Expo has become a benchmark event in the Canadian cannabis industry, known for its high-profile speakers, diverse programming, and commitment to bringing together forward-thinkers and experts. For more information, visit Grow Up Conference & Expo.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE High Tide Inc.
Latest News
Kona Gold Beverages, Inc. Indicates Strategic Expansion Through $5 Million Non-Dilutive Credit Line
Kona Gold Beverages, Inc. (OTCPK: KGKG), a dynamic holding company specializing in product development within the better-for-you and functional beverage sector, is proud to announce the company has successfully secured a $5 million line of credit that will be dedicated to driving production growth, expanding market share, and exploring potential acquisitions.
Under the visionary leadership of the new management team, Kona Gold Beverages, Inc. is taking a bold step toward sustained growth. The $5 million credit line is non-dilutive, meaning it does not have the option to convert into shares of the company. This strategic move emphasizes the management’s commitment to preserving shareholder value and ensuring responsible financial stewardship.
“This non-dilutive credit line marks a significant milestone for Kona Gold Beverages, Inc. as we strategically position ourselves for growth without compromising the interests of our valued shareholders,” said Brandon White, President and Chairman of Kona Gold Beverages, Inc., “We understand the importance of responsible expansion, and this credit line will play a pivotal role in driving our production capabilities, expanding our market presence, and exploring potential acquisitions that align with our vision.”
Management acknowledges the challenge of a bloated share structure inherited from previous funding sources, including the issuance of shares, warrants, and conversion abilities. While some conversion possibilities may be beyond our control, the new management team is fully committed to transparency and will keep shareholders informed of any developments.
The company is actively taking steps to eliminate conversion possibilities within its control, recognizing the significance of growing the company without diluting shareholder value. Additionally, Kona Gold Beverages, Inc. remains dedicated to seeking funding sources that not only align with the company’s growth objectives but also prioritize the best interests of its shareholders and their value.
Key Highlights:
- Strategic Credit Line: The $5 million non-dilutive credit line will be used for production growth, market share expansion, and potential acquisitions.
- Preserving Shareholder Value: The credit line is structured to safeguard shareholder value by preventing conversion into shares of the company.
- Transparency Commitment: Management is fully committed to transparency and will keep shareholders informed regarding the share structure and any potential conversion developments.
- Responsible Financial Stewardship: The new management team is focused on eliminating conversion possibilities within its control and seeking funding sources aligned with shareholder interests.
Kona Gold Beverages, Inc. is poised for an exciting phase of growth, and this strategic financial move underlines the company’s dedication to responsible expansion and shareholder value.
The Company recently announced it has eliminated $1.3 Million in debt and has reduced its authorized shares by 4.386 Billion shares.
For more information regarding Kona Gold Beverage, please visit: https://konagoldbeverage.com/
About Kona Gold Beverage, Inc.
Kona Gold Beverage, Inc., a Delaware corporation, operates its wholly-owned subsidiary, Kona Gold LLC. Kona Gold, LLC has developed a premium Hemp-Infused Energy Drink line; please visit its website at www.konagoldhemp.com. Kona Gold is located on the east coast of Florida in Rockledge.
Safe Harbor Statement:
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions. The Company may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. There can be no assurance that such statements will prove to be accurate. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those outlined in the Company’s Annual Reports on Form 10-K and its other filings with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company’s control. The Company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.
Investor Relations Contact:
844-714-2224
[email protected]
SOURCE Kona Gold Beverage, Inc.
-
Avant2 weeks agoAvant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
-
StickIt2 weeks agoStickIt Technologies Inc. Announces Year-End 2023 Financial Results
-
Cannabis1 week ago
Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology
-
Cannabis1 week ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis1 week agoAvicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis1 week ago
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Cannabis1 week ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services
-
Cannabis1 week ago
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
